Fast depressive symptoms improvement in bipolar I disorder after Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A two-site feasibility and safety open-label trial
Journal of Affective Disorders · 2024
DOI: 10.1016/j.jad.2024.08.087 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Journal of Affective Disorders, 2024. Verfasst von Kevin Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kevinli@jhmi.ed…. Hauptthemen laut MEDLINE: Bipolar Disorder, Feasibility Studies, Magnetic Resonance Imaging, Transcranial Magnetic Stimulation. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NIAAA NIH HHS.
Themen: Depression
Abstract (Originalsprache)
BACKGROUND: Although there are a few first-line treatment options for bipolar depression, none are rapid-acting. A new rTMS protocol, Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT®), has been shown to have a rapid antidepressant effect in major depressive disorder (MDD). We examined the preliminary safety, tolerability, and efficacy of SAINT for the treatment of depression in a small sample of persons with treatment-resistant bipolar I disorder. METHODS: Participants with treatment-resistant bipolar I disorder currently experiencing moderate to severe depression were treated with open-label SAINT. Resting-state functional MRI (fMRI) was used to generate individualized treatment targets for each participant based on the region of the left dorsolateral prefrontal cortex most anticorrelated with the subgenual anterior cingulate cortex. Participants were treated with 10 iTBS sessions daily, with 50-min intersession intervals, for up to 5 consecutive days. The primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) from baseline to immediate follow-up after treatment. RESULTS: We treated 10 participants and found a mean reduction of 16.9 in MADRS scores, with a 50 % response rate and 40 % remission rate immediately following treatment. 60 % of participants met remission criteria within the 1-month period following treatment. No serious adverse events, manic episodes, or cognitive side effects were observed. LIMITATIONS: Our study has a limited sample size and larger samples are needed to confirm safety and efficacy. CONCLUSIONS: SAINT has shown preliminary feasibility, safety, tolerability, and efficacy in treating treatment-resistant bipolar I depression. Double-blinded sham-controlled trials with larger samples are needed to confirm safety and efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: kevinli@jhmi.edu.
- Department of Psychiatry and Behavioral Sciences, University of Texas at Austin Dell Medical School, Austin, TX, USA.
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- Magnus Medical, Burlingame, CA, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Förderung
- NIMH NIH HHS
- NIAAA NIH HHS
Zitieren
APA
Li, K., Bichlmeier, A., DuPont, C., Siegel-Ramsay, J. E., Comfort, A., Logue, E., Stimpson, K. H., Bentzley, B., Williams, N., Reti, I., Almeida, J., & Zandi, P. (2024). Fast depressive symptoms improvement in bipolar I disorder after Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A two-site feasibility and safety open-label trial. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2024.08.087
Vancouver
Li K, Bichlmeier A, DuPont C, Siegel-Ramsay JE, Comfort A, Logue E, et al. Fast depressive symptoms improvement in bipolar I disorder after Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A two-site feasibility and safety open-label trial. Journal of Affective Disorders. 2024. doi:10.1016/j.jad.2024.08.087
BibTeX
@article{Li2024,
author = {Li, Kevin and Bichlmeier, Amy and DuPont, Caitlin and Siegel-Ramsay, Jennifer E and Comfort, Alexa and Logue, Erin and Stimpson, Katy H and Bentzley, Brandon and Williams, Nolan and Reti, Irving and Almeida, Jorge and Zandi, Peter},
title = {Fast depressive symptoms improvement in bipolar I disorder after Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A two-site feasibility and safety open-label trial},
journal = {Journal of Affective Disorders},
year = {2024},
doi = {10.1016/j.jad.2024.08.087}
}
EUVIMED